Anti-CD228/MMAE Antibody-drug Conjugate PF-08046031

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) antibody targeting the cell surface antigen cluster of differentiation 228 (CD228; melanotransferrin; MFI2; MELTF; p97; MTf) that is conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-CD228/MMAE ADC PF-08046031 targets and binds to CD228 on the surface of tumor cells. Following internalization of PF-08046031 and transport to lysosomes, MMAE is released, binds to tubulin, and inhibits microtubule polymerization. This results in microtubule disruption and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins. CD228 expression is elevated in multiple solid tumors but has limited expression in normal tissues.

**Synonyms:** - Anti-CD228 ADC PF-08046031 - Anti-CD228 Antibody-drug Conjugate PF-08046031 - Anti-CD228-MMAE ADC PF-08046031 - Anti-CD228/MMAE ADC PF-08046031 - Anti-melanotransferrin ADC PF-08046031 - PF 08046031 - PF-08046031 - PF08046031